NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $1.16 +0.01 (+0.87%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Aclaris Therapeutics Stock (NASDAQ:ACRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$1.13▼$1.1750-Day Range$1.12▼$1.3452-Week Range$0.59▼$6.16Volume257,477 shsAverage Volume1.01 million shsMarket Capitalization$82.67 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingHold Company OverviewAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Aclaris Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks73rd Percentile Overall ScoreACRS MarketRank™: Aclaris Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 279th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAclaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aclaris Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aclaris Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.40% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 0.58%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.40% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 0.58%, indicating that investor sentiment is improving. News and Social Media3.5 / 5News Sentiment1.22 News SentimentAclaris Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aclaris Therapeutics this week, compared to 2 articles on an average week.Search Interest18 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 157% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $418,823.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. ACRS Stock News HeadlinesAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Price Target from AnalystsOctober 8 at 1:31 AM | americanbankingnews.comAclaris Therapeutics (NASDAQ:ACRS) Stock, Short Interest ReportOctober 7 at 11:07 PM | benzinga.comEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during This 8-Day Profit Window? And when I say almost always… I really mean it. For over a year now, traders have had the chance to cash in during this time with an 83% success rate using these New Bitcoin Options. Now of course I can’t promise future returns or against losses…October 8, 2024 | DTI (Ad)Aclaris Therapeutics (ACRS) Gets a Hold from H.C. WainwrightSeptember 18, 2024 | markets.businessinsider.comAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic DermatitisSeptember 17, 2024 | globenewswire.comAclaris Therapeutics Engages in 2024 Cantor Global Healthcare ConferenceSeptember 12, 2024 | msn.comAclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comH.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)August 20, 2024 | markets.businessinsider.comSee More Headlines ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $1.05 on January 1st, 2024. Since then, ACRS shares have increased by 10.5% and is now trading at $1.16. View the best growth stocks for 2024 here. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The biotechnology company had revenue of $2.77 million for the quarter, compared to analysts' expectations of $1.74 million. Aclaris Therapeutics had a negative net margin of 183.28% and a negative trailing twelve-month return on equity of 53.18%. Who are Aclaris Therapeutics' major shareholders? Top institutional shareholders of Aclaris Therapeutics include Trium Capital LLP (2.68%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion, Kevin Balthaser and Frank Ruffo. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/07/2024Today10/08/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Target$23.50 High Stock Price Target$38.00 Low Stock Price Target$9.00 Potential Upside/Downside+1,943.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,480,000.00 Net Margins-183.28% Pretax Margin-184.43% Return on Equity-53.18% Return on Assets-41.74% Debt Debt-to-Equity RatioN/A Current Ratio7.50 Quick Ratio7.50 Sales & Book Value Annual Sales$32.02 million Price / Sales2.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.52Miscellaneous Outstanding Shares71,265,000Free Float66,704,000Market Cap$81.95 million OptionableOptionable Beta0.20 Social Links This page (NASDAQ:ACRS) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Aclaris Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.